Ultra Market Research | United States Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market
United States Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market
Report ID : 854
Category : Pharmaceuticals,United-States(US)
No Of Pages : 176
Published on: November 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United States Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market
Introduction
The United States ATTR-CM market is centered on managing transthyretin amyloid cardiomyopathy, a rare but progressively debilitating condition caused by amyloid protein deposits in the heart. ATTR-CM is classified into hereditary and wild-type forms, both resulting in heart failure and reduced quality of life if left untreated. The United States leads the global market in ATTR-CM diagnostics and therapeutics, driven by advanced healthcare infrastructure, patient awareness, and ongoing research. Innovations in pharmacological therapies, gene-silencing drugs, and diagnostic imaging solutions dominate the U.S. ATTR-CM market. With the increasing prevalence of ATTR-CM, particularly in aging populations, the market is expected to experience significant growth in the coming years.
Segmentation
By Treatment Type
Pharmacological Therapies
Tafamidis
Diflunisal
Non-steroidal anti-inflammatory Drugs (NSAIDs)
Others
Gene Silencing Therapies
Patisiran
Inotersen
Supportive Therapies
Beta-Blockers
Diuretics
Anti-arrhythmic Drugs
By Diagnostics
Imaging Techniques
Echocardiography
Cardiac MRI
Nuclear Imaging
Others
Biomarker Testing
NT-proBNP Testing
Troponin Testing
Others
Genetic Testing
Mutation Analysis
Family History Testing
By End-User
Hospitals and Clinics
Cardiology Departments
Specialty Clinics
Diagnostic Laboratories
Independent Laboratories
Hospital-Affiliated Labs
Research and Academic Institutes
By Distribution Channel
Hospital Pharmacies
Inpatient Dispensing
Specialty Drug Distribution
Retail Pharmacies
Chain Pharmacies
Standalone Pharmacies
Online Pharmacies
List of Market Players
Pfizer Inc. (United States)
Alnylam Pharmaceuticals (United States)
Eidos Therapeutics (United States)
Ionis Pharmaceuticals (United States)
BridgeBio Pharma (United States)
AstraZeneca (United Kingdom)
GlaxoSmithKline (United Kingdom)
Johnson & Johnson (United States)
Novartis AG (Switzerland)
Sanofi (France)
Prothena Corporation (United States)
Regeneron Pharmaceuticals (United States)
Merck & Co. (United States)
Amgen Inc. (United States)
Bristol-Myers Squibb (United States)
Drivers
The United States ATTR-CM market is driven by advancements in medical technologies, increased awareness, and the rising prevalence of the disease. An aging population contributes significantly to the growth of wild-type ATTR-CM cases. U.S.-based pharmaceutical companies are leading in the development of groundbreaking therapies, including transthyretin stabilizers and RNA-based gene silencing drugs. Strong regulatory support and expedited FDA approvals for rare disease drugs enhance market accessibility. Improved diagnostic methods, such as advanced imaging techniques and biomarker tests, facilitate early detection and better disease management. Increased focus on precision medicine also boosts the adoption of personalized treatment approaches, driving market growth.
Restraints
Challenges in the United States ATTR-CM market include high costs associated with treatment and diagnostic technologies, limiting accessibility for uninsured or underinsured patients. The rarity of the disease results in delayed diagnoses, as many clinicians are unfamiliar with its symptoms. Additionally, overlapping symptoms with other cardiac conditions lead to misdiagnosis or underdiagnosis. Regulatory hurdles for clinical trials, including stringent FDA requirements, can delay drug approvals. Limited awareness among patients and primary care physicians about ATTR-CM further impacts timely treatment.
Opportunity
The United States ATTR-CM market offers substantial opportunities through investments in research and development for novel therapeutics and diagnostics. Expansion of genetic screening programs can enable earlier detection of hereditary ATTR-CM cases. Collaborative partnerships between healthcare providers, pharmaceutical companies, and academic institutions can facilitate faster innovation. Increasing adoption of telemedicine services provides opportunities to enhance access to care in remote regions. Furthermore, rising healthcare expenditure in the U.S. creates a favorable environment for the adoption of premium diagnostic and therapeutic solutions.
Trend
Recent trends in the United States ATTR-CM market highlight the integration of artificial intelligence (AI) in diagnostic imaging, improving accuracy and reducing the time for diagnosis. Gene editing technologies like CRISPR are being explored as potential treatments for hereditary ATTR-CM. The use of wearable health monitors for real-time cardiac function tracking is gaining traction. Personalized medicine approaches, tailored to individual genetic profiles, are becoming mainstream. Additionally, patient-centric models of care, supported by digital health platforms, are transforming disease management strategies.
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of United States market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United States Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue United Statesly. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United States Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market for the past year and forecasts for the next six years. United States Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market. Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United States Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market categories. Market size and forecasts for each major application is provided in the context of United States market. The numbers provided in this report are derived on the basis of demand for United States Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market from different application industries in different regions.
